A compound is represented by a formula (1). n is 2 to 4, m is 1 to 4, q is 0 to 3, and m+n+q=6; CN is a cyano group; D.sub.1 is a group represented by a formula (2), (3) or (3X), the plurality of D.sub.1 are the same; and Rx is a hydrogen atom or substituent. R.sub.1 to R.sub.8 are each independently a hydrogen atom or substituent. R.sub.31 to R.sub.38 and R.sub.41 to R.sub.48 are each independently a hydrogen atom or substituent; p, px and py are each independently 1 to 4; A to C are each independently a cyclic structure represented by a formula (131) or (132). R.sub.19 and R.sub.20 are each independently a hydrogen atom or substituent. X.sub.1 is a sulfur atom or the like, and * represents a bonding position with a carbon atom of a benzene ring in the formula (1).

##STR00001##

A compound is represented by a formula (1). n is 2 to 4, m is 1 to 4, q is 0 to 3, and m+n+q=6; CN is a cyano group; D.sub.1 is a group represented by a formula (2), (3) or (3X), the plurality of D.sub.1 are the same; and Rx is a hydrogen atom or substituent. R.sub.1 to R.sub.8 are each independently a hydrogen atom or substituent. R.sub.31 to R.sub.38 and R.sub.41 to R.sub.48 are each independently a hydrogen atom or substituent; p, px and py are each independently 1 to 4; A to C are each independently a cyclic structure represented by a formula (131) or (132). R.sub.19 and R.sub.20 are each independently a hydrogen atom or substituent. X.sub.1 is a sulfur atom or the like, and * represents a bonding position with a carbon atom of a benzene ring in the formula (1).

##STR00001##

The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.

The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.

The present invention discloses a number of polycyclic amines that are useful as opioid receptor modulators. The compounds of the invention are useful in both therapeutic and diagnostic methods, including for treating pain, neurological disorders, cardiac disorders, bowel disorders, drug and alcohol addiction, drug overdose, urinary disorders, respiratory disorders, sexual dysfunction, psoriasis, graft rejection or cancer.

The present invention discloses a number of polycyclic amines that are useful as opioid receptor modulators. The compounds of the invention are useful in both therapeutic and diagnostic methods, including for treating pain, neurological disorders, cardiac disorders, bowel disorders, drug and alcohol addiction, drug overdose, urinary disorders, respiratory disorders, sexual dysfunction, psoriasis, graft rejection or cancer.

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.